7BS protein arginine methyltranferases

CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of an oversubscribed $62M Series C funding round. The Series C financing round was led by New Enterprise Associates (NEA) with participation from Revolution Growth and other existing insiders. This new capital infusion will enable Pathos to expand its team of world-class scientists and engineers, accelerate the development of its AI-powered drug development platform, and advance its clinical-stage pipeline of precision oncology therapeutics. This latest round, which also included its existing investors, Lightbank and Builders VC, was completed at a $600 million post money valuation, bringing the three-year-old company’s total funding to $102M. In the last 12 months, Pathos has acquired two clinical-stage precision oncology assets with plans to launch the next clinical trials in 2025. For both therapeutics, P-300 and P-500, the PATHOSTM platform is fueling its patient selection strategy and clinical trial design to improve the likelihood of success. For example, Pathos was able to prioritize certain biological mechanisms that are relevant for P-500, a phase-II ready, brain-penetrant PRMT5 inhibitor, and those same mechanisms were driving different patient outcomes for a subgroup of IDH+ high-grade glioma patients in the real-world. This insight can help identify the patients most likely to benefit from P-500 and explain mechanistically why certain patients responded to P-500 while others did not respond in the Phase I clinical trial. Pathos plans to translate this insight into an enhanced patient selection strategy and launch the next clinical trial to demonstrate an improved efficacy signal. “There are hundreds of investigational drugs with phase I results demonstrating a tolerable safety profile and modest efficacy, yet too many of these drugs go on to fail in future phases in clinical trials. By leveraging AI to understand why some patients respond and others do not, we believe we can materially increase the probability of successful trials, accelerate development through the clinic, and help resurrect failed or shelved compounds for the patients they were meant to serve,” said Ryan Fukushima, Interim CEO of Pathos. “We are excited to work alongside a great group of investors that share our passion to radically improve drug development. This funding will allow us to scale our operations and translate our insights to improve the lives of patients at an accelerated pace.” “We believe Pathos’ mission to revolutionize drug discovery and development by combining best-in-class AI capabilities with large libraries of clinical patient data resonates with NEA’s storied history of investing at the intersection of technology and life science,” said Mohamad Makhzoumi, Co-CEO, NEA. “We are thrilled to lead Pathos’ Series C financing and to bring our expertise to this strategic partnership as Ryan and the pathos team work to pioneer the future of precision medicine.” With an initial focus on phase II oncology clinical trials, Pathos is applying its AI platform to acquire additional clinical stage opportunities with phase I results, demonstrating a safe and tolerable profile. Pathos is systematically identifying causal links of critical biological mechanisms that drive certain cancers and lead to worse patient outcomes in the real-world. With this information, Pathos prioritizes critical biological mechanisms and acquires great drugs with the relevant mechanisms of action to attack cancers in particular patient sub-populations. By pairing the right patient selection strategies with great oncology therapeutics, Pathos believes it can partner with biopharma to usher in the next era of precision medicine and improve the current success rates in clinical trials at the same time. About PathOSTM PlatformWe have built a proprietary platform and operating model called PathOS™ to gain crucial insights and act on them at scale. We do this using a causal AI framework analyzing changes in expression levels across all genes which are both associated with overall survival and known to be regulated by the mechanism of a given drug. Our AI models are fueled by one of the largest multimodal real-world datasets with patient outcomes, DNA sequencing and RNA sequencing data. By combining our in silico insights with ex-vivo drug screening approaches, we orthogonally verify whether our patient selection strategies are predictive of future patient benefit prior to designing our phase II clinical trials. About PathosPathos is an AI-enabled biotechnology company focused on re-engineering drug development, leveraging the power of technology to bring precision medicine to patients through partnerships with pharmaceutical companies. Pathos has raised over $100 million to accelerate the development of precision medicines and to expand its platform, combining computational approaches across multimodal real-world data and patient-derived biological models. Additional information can be found at www.pathos.com. ContactsBusiness Development: bd@pathos.comPress Inquiries: press@pathos.com

KRAKOW, Poland, Oct. 29, 2024 /PRNewswire/ -- Ryvu Therapeutics and nCage Therapeutics are pleased to announce that they have entered a research collaboration to develop a next-generation antibody-drug conjugate (ADC) platform. nCage has developed a TRAP cage platform where the protein cages are synthetic virus-like particles (VLPs) that can be used to display biological material on their surface or transport molecules such as nucleic acids or proteins into the interior of a target cell. This collaboration is focusing on the latter where a TRAP cage can be utilized as a novel drug delivery system (DDS) that could improve the efficacy and safety of current ADCs. The partners are encouraged by the potential of nCage's TRAP cage platform to improve the antibody-to-drug ratio (DAR) compared to currently approved ADCs. An improved DAR could result in greater efficacy and safety for novel ADCs. ADCs are a growing drug class that has achieved excellent results in clinical trials. However, over 40% of patients experience severe side effects. Improving the DAR will allow for less toxic drug payloads and should expand the applicable patient population. Ryvu and nCage foresee a long-term partnership that will significantly enhance the TRAP cage for drug delivery, potentially leading to breakthrough oncology therapies. nCage CEO, John Bason, stated: Our promising vaccine data suggests that we can develop best-in-class products for numerous viral targets. We are excited about the potential for this partnership with Ryvu to help us develop a second arm of the company, further driving the development of the company. Ryvu Chief Scientific Officer, Krzysztof Brzózka notes: This collaboration is an exciting opportunity to combine our small molecule expertise and experience with novel ADC payloads with the strong team at nCage, who are working on a truly novel delivery platform. We are encouraged by the growing field of next-generation ADCs and the potential for this collaboration to generate more effective and safer therapies. Ryvu and nCage will each support their own costs in executing this collaboration, and all data generated through the collaboration will be jointly owned. Ryvu and nCage look forward to sharing more about the collaboration as the work progresses. About Ryvu Therapeutics Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinases, synthetic lethality, and immuno-oncology targets. Ryvu's most advanced program is RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies and solid tumors. RVU120 is currently in Phase II development (i) as a monotherapy for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and high-risk myelodysplastic syndromes (HR-MDS) – the RIVER-52 study, (ii) in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, and (iii) as a monotherapy for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) – the REMARK study. MEN1703 (SEL24) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is expected to start a Phase II study in diffuse large B-cell lymphoma (DLBCL) in Q4 2024. RVU305, a potentially best-in-class PRMT5 inhibitor aiming to treat multiple solid tumors, is currently undergoing IND/CTA-enabling studies. Ryvu Therapeutics has signed 11 partnering and licensing deals with global companies, including BioNTech and Exelixis. The company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the mWIG40 index. For more information, please see . About nCage Therapeutics nCage Therapeutics is a biopharmaceutical company developing its innovative synthetic VLP platform technology to develop vaccines against infectious diseases and second-generation antibody-drug conjugates (ADCs). nCage's VLP platform utilizes a universal hook system to display antigens or biological targeting moieties on the exterior of a protein scaffold and load a peptide antigen or a drug payload on the interior of the VLP. Vaccines developed using the platform induce broad, robust, and durable protection against the specific viruses targeted. Drug delivery system is characterized by a controlled release of cytotoxic payload and should have a superior safety and toxicity profile to ADCs that are currently on the market. nCage's lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and other respiratory viruses. Its pipeline includes additional combination and respiratory vaccine candidates, including influenza and SARS-CoV-2. nCage Therapeutics was founded in 2019 to advance the breakthrough synthetic VLP technology developed in the Malopolska Centre of Biotechnology (MCB) of Jagiellonian University in Krakow. nCage is located in Krakow. For more information, please see . SOURCE Ryvu Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Chicago startup Pathos AI has completed a $62 million Series C to keep looking for Phase 1 cancer drugs that it can acquire and test in more specific patient populations, it said Tuesday morning. The round, at a $600 million post-money valuation, brings the three-year-old biotech’s total funding to $102 million. Pathos is derived from executives of Tempus , the AI healthcare company partnered with many big drugmakers. While many AI-driven biotech startups are using the technology to create new drugs, Pathos said it is using AI to scour for experimental treatments already in the clinic that it can test in new trials with patients who are more likely to respond. The goal is to “materially increase the probability of successful trials, accelerate development through the clinic, and help resurrect failed or shelved compounds for the patients they were meant to serve,” CEO Ryan Fukushima said in a release. He’s also operating chief of Tempus. Since its founding, Pathos has already acquired three clinical-stage drugs: Prelude Therapeutics ‘ PRMT5 inhibitor; a takeover of Rain Oncology ; and a licensing deal for Novo Nordisk’s CBP/p300 inhibitor . It also bought a machine learning startup called Known Medicine in 2023. Pathos said it will launch new clinical trials next year for medicines it has bought. New Enterprise Associates led the Series C. Other investors include Revolution Growth, Builders VC and Lightbank, a VC firm co-founded by Tempus CEO Eric Lefkofsky.